Osteoporosis International

, Volume 23, Issue 7, pp 2017–2025 | Cite as

FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages

  • L. Desjardins
  • S. Liabeuf
  • C. Renard
  • A. Lenglet
  • H.-D. Lemke
  • G. Choukroun
  • T. B. Drueke
  • Z. A. Massy
  • on behalf of the European Uremic Toxin (EUTox) Work Group
Original Article



The hormone fibroblast growth factor 23 (FGF23) is involved in mineral homeostasis but may also have a role in vascular calcification and bone mineralization. In a cohort of 142 patients with CKD stages 2–5D, plasma FGF23 was independently associated with aortic calcification but not with pulse wave velocity or bone mineral density.


FGF23 is involved in mineral homeostasis but may also have a role in vascular calcification and bone mineralization. Previous studies related to FGF23 and vascular and bone outcomes have been restricted to dialysis patients. The aim of the present study was to establish whether or not plasma FGF23 is associated with aortic and coronary calcification, arterial stiffness, and bone mineral density in patients with early as well as late stages of CKD.


In a cohort of 142 patients with CKD stages 2–5D, we made routine biochemistry and intact FGF23 determinations, and assessed aortic and coronary calcification, bone mineral density (BMD), and arterial stiffness by multislice spiral computed tomography and automated pulse wave velocity (PWV).


Plasma intact FGF23 levels were elevated in CKD patients; the elevation preceded that of serum phosphate in early-stage CKD. Patients with elevated FGF23 levels had higher aortic and coronary calcification scores than patients with lower FGF23 levels. Multivariate linear regression analysis indicated that only age (p < 0.001) and FGF23 (p = 0.008) were independently associated with aortic calcification score. Plasma FGF23 was neither associated with PWV nor with BMD.


Our data suggest that plasma FGF23 is an independent biomarker of vascular calcification in patients with various CKD stages including early stages. The association between vascular calcification and FGF23 levels appears to be independent of BMD. It remains to be seen whether this association is independent of bone turnover and bone mass.


Bone mineral density Chronic kidney disease CKD stage FGF23 Pulse wave velocity Vascular calcification 


Conflicts of interest



  1. 1.
    Liu S, Guo R, Simpson LG, Xiao ZS, Burnham CE, Quarles LD (2003) Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem 278:37419–37426PubMedCrossRefGoogle Scholar
  2. 2.
    Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, Iwasaki H, Iida A, Shiraki-Iida T, Nishikawa S, Nagai R, Nabeshima YI (1997) Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390:45–51PubMedCrossRefGoogle Scholar
  3. 3.
    Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T (2004) FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19:429–435PubMedCrossRefGoogle Scholar
  4. 4.
    Nakanishi S, Kazama JJ, Nii-Kono T, Omori K, Yamashita T, Fukumoto S, Gejyo F, Shigematsu T, Fukagawa M (2005) Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. Kidney Int 67:1171–1178PubMedCrossRefGoogle Scholar
  5. 5.
    Shimada T, Muto T, Urakawa I, Yoneya T, Yamazaki Y, Okawa K, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T (2002) Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology 143:3179–3182PubMedCrossRefGoogle Scholar
  6. 6.
    Isakova T, Wahl P, Vargas GS, Gutierrez OM, Scialla J, Xie H, Appleby D, Nessel L, Bellovich K, Chen J, Hamm L, Gadegbeku C, Horwitz E, Townsend RR, Anderson CA, Lash JP, Hsu CY, Leonard MB, Wolf M (2011) Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 79:1370–1378PubMedCrossRefGoogle Scholar
  7. 7.
    Vanholder R, Massy Z, Argiles A, Spasovski G, Verbeke F, Lameire N (2005) Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 20:1048–1056PubMedCrossRefGoogle Scholar
  8. 8.
    Foley RN, Parfrey PS, Sarnak MJ (1998) Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32:S112–S119PubMedCrossRefGoogle Scholar
  9. 9.
    Taal MW, Roe S, Masud T, Green D, Porter C, Cassidy MJ (2003) Total hip bone mass predicts survival in chronic hemodialysis patients. Kidney Int 63:1116–1120PubMedCrossRefGoogle Scholar
  10. 10.
    Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Juppner H, Wolf M (2008) Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359:584–592PubMedCrossRefGoogle Scholar
  11. 11.
    Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM (1999) Impact of aortic stiffness on survival in end-stage renal disease. Circulation 99:2434–2439PubMedGoogle Scholar
  12. 12.
    Jean G, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, Chazot C (2009) High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant 24:2792–2796PubMedCrossRefGoogle Scholar
  13. 13.
    Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, Gutierrez OM, Steigerwalt S, He J, Schwartz S, Lo J, Ojo A, Sondheimer J, Hsu CY, Lash J, Leonard M, Kusek JW, Feldman HI, Wolf M (2011) Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 305:2432–2439PubMedCrossRefGoogle Scholar
  14. 14.
    Nasrallah MM, El-Shehaby AR, Salem MM, Osman NA, El Sheikh E, Sharaf El Din UA (2010) Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification in haemodialysis patients. Nephrol Dial Transplant 25:2679–2685PubMedCrossRefGoogle Scholar
  15. 15.
    Jean G, Bresson E, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, Chazot C (2009) Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences. Nephrol Dial Transplant 24:948–955PubMedCrossRefGoogle Scholar
  16. 16.
    Temmar M, Liabeuf S, Renard C, Czernichow S, Esper NE, Shahapuni I, Presne C, Makdassi R, Andrejak M, Tribouilloy C, Galan P, Safar ME, Choukroun G, Massy Z (2010) Pulse wave velocity and vascular calcification at different stages of chronic kidney disease. J Hypertens 28:163–169PubMedCrossRefGoogle Scholar
  17. 17.
    Nakano T, Ninomiya T, Sumiyoshi S, Fujii H, Doi Y, Hirakata H, Tsuruya K, Iida M, Kiyohara Y, Sueishi K (2010) Association of kidney function with coronary atherosclerosis and calcification in autopsy samples from Japanese elders: the Hisayama study. Am J Kidney Dis 55:21–30PubMedCrossRefGoogle Scholar
  18. 18.
    Urena P, Bernard-Poenaru O, Ostertag A, Baudoin C, Cohen-Solal M, Cantor T, de Vernejoul MC (2003) Bone mineral density, biochemical markers and skeletal fractures in haemodialysis patients. Nephrol Dial Transplant 18:2325–2331PubMedCrossRefGoogle Scholar
  19. 19.
    Manghat P, Fraser WD, Wierzbicki AS, Fogelman I, Goldsmith DJ, Hampson G (2010) Fibroblast growth factor-23 is associated with C-reactive protein, serum phosphate and bone mineral density in chronic kidney disease. Osteoporos Int 21:1853–1861PubMedCrossRefGoogle Scholar
  20. 20.
    Mirza MA, Larsson A, Lind L, Larsson TE (2009) Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis 205:385–390PubMedCrossRefGoogle Scholar
  21. 21.
    Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41PubMedCrossRefGoogle Scholar
  22. 22.
    Fassbender WJ, Brandenburg V, Schmitz S, Sandig D, Simon SA, Windolf J, Stumpf UC (2009) Evaluation of human fibroblast growth factor 23 (FGF-23) C-terminal and intact enzyme-linked immunosorbent-assays in end-stage renal disease patients. Clin Lab 55:144–152PubMedGoogle Scholar
  23. 23.
    Stevens LA, Coresh J, Schmid CH, Feldman HI, Froissart M, Kusek J, Rossert J, Van Lente F, Bruce RD 3rd, Zhang YL, Greene T, Levey AS (2008) Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis 51:395–406PubMedCrossRefGoogle Scholar
  24. 24.
    National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39:S1–S266CrossRefGoogle Scholar
  25. 25.
    Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano R (1990) Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 15:827–832PubMedCrossRefGoogle Scholar
  26. 26.
    Raggi P, James G, Burke SK, Bommer J, Chasan-Taber S, Holzer H, Braun J, Chertow GM (2005) Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis. J Bone Miner Res 20:764–772PubMedCrossRefGoogle Scholar
  27. 27.
    Zureik M, Temmar M, Adamopoulos C, Bureau JM, Courbon D, Thomas F, Bean K, Touboul PJ, Ducimetiere P, Benetos A (2002) Carotid plaques, but not common carotid intima-media thickness, are independently associated with aortic stiffness. J Hypertens 20:85–93PubMedCrossRefGoogle Scholar
  28. 28.
    Asmar R, Benetos A, Topouchian J, Laurent P, Pannier B, Brisac AM, Target R, Levy BI (1995) Assessment of arterial distensibility by automatic pulse wave velocity measurement. Validation and clinical application studies. Hypertension 26:485–490PubMedGoogle Scholar
  29. 29.
    Barreto DV, Barreto FC, Liabeuf S, Temmar M, Boitte F, Choukroun G, Fournier A, Massy ZA (2009) Vitamin D affects survival independently of vascular calcification in chronic kidney disease. Clin J Am Soc Nephrol 4:1128–1135PubMedCrossRefGoogle Scholar
  30. 30.
    Gutierrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, Sarwar A, Hoffmann U, Coglianese E, Christenson R, Wang TJ, deFilippi C, Wolf M (2009) Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 119:2545–2552PubMedCrossRefGoogle Scholar
  31. 31.
    Stubbs JR, Liu S, Tang W, Zhou J, Wang Y, Yao X, Quarles LD (2007) Role of hyperphosphatemia and 1,25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice. J Am Soc Nephrol 18:2116–2124PubMedCrossRefGoogle Scholar
  32. 32.
    Razzaque MS, Sitara D, Taguchi T, St-Arnaud R, Lanske B (2006) Premature aging-like phenotype in fibroblast growth factor 23 null mice is a vitamin D-mediated process. FASEB J 20:720–722PubMedGoogle Scholar
  33. 33.
    Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T (2001) Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 98:6500–6505PubMedCrossRefGoogle Scholar
  34. 34.
    Ichikawa S, Imel EA, Kreiter ML, Yu X, Mackenzie DS, Sorenson AH, Goetz R, Mohammadi M, White KE, Econs MJ (2007) A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. J Clin Invest 117:2684–2691PubMedCrossRefGoogle Scholar
  35. 35.
    Hu MC, Shi M, Zhang J, Quinones H, Griffith C, Kuro-o M, Moe OW (2010) Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol 22:124–136PubMedCrossRefGoogle Scholar
  36. 36.
    Manghat P, Souleimanova I, Cheung J, Wierzbicki AS, Harrington DJ, Shearer MJ, Chowienczyk P, Fogelman I, Goldsmith D, Hampson G (2011) Association of bone turnover markers and arterial stiffness in pre-dialysis chronic kidney disease (CKD). Bone 48:1127–1132PubMedCrossRefGoogle Scholar
  37. 37.
    Raggi P, Bellasi A, Ferramosca E, Block GA, Muntner P (2007) Pulse wave velocity is inversely related to vertebral bone density in hemodialysis patients. Hypertension 49:1278–1284PubMedCrossRefGoogle Scholar
  38. 38.
    Toussaint ND, Lau KK, Strauss BJ, Polkinghorne KR, Kerr PG (2008) Associations between vascular calcification, arterial stiffness and bone mineral density in chronic kidney disease. Nephrol Dial Transplant 23:586–593PubMedCrossRefGoogle Scholar
  39. 39.
    Sitara D, Kim S, Razzaque MS, Bergwitz C, Taguchi T, Schuler C, Erben RG, Lanske B (2008) Genetic evidence of serum phosphate-independent functions of FGF-23 on bone. PLoS Genet 4:e1000154PubMedCrossRefGoogle Scholar
  40. 40.
    Wesseling-Perry K, Pereira RC, Wang H, Elashoff RM, Sahney S, Gales B, Juppner H, Salusky IB (2009) Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis. J Clin Endocrinol Metab 94:511–517PubMedCrossRefGoogle Scholar
  41. 41.
    Oliveira RB, Cancela AL, Graciolli FG, Dos Reis LM, Draibe SA, Cuppari L, Carvalho AB, Jorgetti V, Canziani ME, Moyses RM (2010) Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin J Am Soc Nephrol 5:286–291PubMedCrossRefGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2011

Authors and Affiliations

  • L. Desjardins
    • 1
    • 2
  • S. Liabeuf
    • 1
    • 2
  • C. Renard
    • 3
  • A. Lenglet
    • 1
    • 2
  • H.-D. Lemke
    • 4
  • G. Choukroun
    • 1
    • 5
  • T. B. Drueke
    • 1
  • Z. A. Massy
    • 1
    • 2
    • 5
    • 6
  • on behalf of the European Uremic Toxin (EUTox) Work Group
  1. 1.INSERM ERI-12 (EA 4292), UFR de Médecine et PharmacieJules Verne University of PicardyAmiensFrance
  2. 2.Clinical Research Centre - Division of Clinical PharmacologyAmiens University Medical Center and the Jules Verne University of PicardyAmiensFrance
  3. 3.Division of RadiologyAmiens University Medical CenterAmiensFrance
  4. 4.EXcorLab GmbHObernburgGermany
  5. 5.Division of NephrologyAmiens University Medical CenterAmiensFrance
  6. 6.INSERM ERI-12 and Divisions of Clinical Pharmacology and NephrologyAmiens University HospitalAmiensFrance

Personalised recommendations